LKB1 modulates lung cancer differentiation and metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Germline mutation in serine/threonine kinase 11 (STK11, also called LKB1) results in Peutz-Jeghers syndrome, characterized by intestinal hamartomas and increased incidence of epithelial cancers. Although uncommon in most sporadic cancers, inactivating somatic mutations of LKB1 have been reported in primary human lung adenocarcinomas and derivative cell lines. Here we used a somatically activatable mutant Kras-driven model of mouse lung cancer to compare the role of Lkb1 to other tumour suppressors in lung cancer. Although Kras mutation cooperated with loss of p53 or Ink4a/Arf (also known as Cdkn2a) in this system, the strongest cooperation was seen with homozygous inactivation of Lkb1. Lkb1-deficient tumours demonstrated shorter latency, an expanded histological spectrum (adeno-, squamous and large-cell carcinoma) and more frequent metastasis compared to tumours lacking p53 or Ink4a/Arf. Pulmonary tumorigenesis was also accelerated by hemizygous inactivation of Lkb1. Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively. Expression profiling in human lung cancer cell lines and mouse lung tumours identified a variety of metastasis-promoting genes, such as NEDD9, VEGFC and CD24, as targets of LKB1 repression in lung cancer. These studies establish LKB1 as a critical barrier to pulmonary tumorigenesis, controlling initiation, differentiation and metastasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond its role regulating metabolism via AMPK, LKB1 loss promotes tumorigenesis by reprogramming epigenetic states, facilitating lineage plasticity and promoting metastasis22,67–70.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [22]
In the citing paper
“Somatic deletion of Lkb1 is insufficient for initiation of lung carcinogenesis in mice as a singular event but dramatically accelerates KrasG12D-driven carcinogenesis and fosters early metastatic dissemination84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“In addition, loss of Lkb1 results in epigenetic reprogramming and an expanded tumor histological repertoire, with high incidence of squamous or adenosquamous carcinomas, in agreement with data supporting enrichment of LKB1 mutations in human adenosquamous NSCLC84–86.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
In the citing paper
“Loss of p53 or expression of either dominant negative or dominant gain-of-function Trp53 mutants also co-operate with oncogenic Kras to induce LUADs with shortened latency and increased metastatic proclivity, although these tumors are less aggressive than those with Lkb1 loss69–71, 84.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [84]
Citations
Cites
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationRole of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
Molecular Definition of Breast Tumor Heterogeneity
Shipitsin, M., Campbell, L. L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.01.013 · Cited by 1,353
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 1×
“Only point mutation or deletion 8 of 80 (10) 4 of 42 (10) 1 of 22 (5) 13 of 144 (9) Only single-copy loss by MLPA 11 of 80 (14) 2 of 42 (5) 1 of 22 (5) 14 of 144 (10) Homozygous mutation or deletion 8{ of 80 (10) 2 of 42 (5) 0 of 22 (0) 10 of 144 (7) Total 27 of 80 (34) 8 of 42 (19) 2 of 22 (9) 37 of 144 (26)”
Self-citationThe LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
Self-citation
Cited by
Items 401–500 of 1,000
Stein, B. D., Ferrarone, J. R., Gardner, E. E., Chang, J. W., Wu, D., Hollstein, P. E., Liang, R. J., Yuan, M., Chen, Q., Coukos, J. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0805 · Cited by 49
“The median survival of mice receiving Lenti-Cre/ sgNT (KLN) was 52 days, in line with previous reports on the latency of KL lung tumorigenesis (24, 48–51).”
TIMP1 is an early biomarker for detection and prognosis of lung cancer
Dantas, E., Murthy, A., Ahmed, T., Ahmed, M., Ramsamooj, S., Hurd, M. A., Lam, T., Malbari, M. S., Agrusa, C. J., Elemento, O., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1391 · Cited by 55
Energy sensing and cancer: LKB1 function and lessons learnt from Peutz–Jeghers syndrome
Shorning, B. Y., & Clarke, A. R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.015 · Cited by 47
Functional characterization of AMP-activated protein kinase signaling in tumorigenesis
Cheng, J., Zhang, T., Ji, H., Tao, K., Guo, J., & Wei, W. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.006 · Cited by 47
Self-citationLKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors
Caiola, E., Iezzi, A., Tomanelli, M., Bonaldi, E., Scagliotti, A., Colombo, M., Guffanti, F., Micotti, E., Garassino, M. C., Minoli, L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.009 · Cited by 47
“It has been reported that the KRAS/LKB1 double mutation in murine lung tumors promotes tumor burden, invasion, and metastasis.(28,29) Our data suggest that ERK inhibition could also be effective in tumors harboring KRAS/LKB1 double mutation, thus increasing the therapeutic strategies for this prognostically unfavorabl…”
BackgroundEpithelial cell plasticity defines heterogeneity in lung cancer
Sarode, P., Mansouri, S., Karger, A., Schaefer, M. B., Grimminger, F., Seeger, W., & Savai, R. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109463 · Cited by 49
Preclinical models and technologies to advance nanovaccine development
Peres, C., Matos, A. I., Moura, L. I. F., Acúrcio, R. C., Carreira, B., Pozzi, S., Vaskovich‐Koubi, D., Kleiner, R., Satchi‐Fainaro, R., & Florindo, H. F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.03.001 · Cited by 48
Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery
Aldea, M. D., Craciun, L., Tomuleasa, C., Berindan‐Neagoe, I., Kacsó, G., Florian, I. Ş., & Crivii, C. B. (2014) · Tumor Biology · doi:10.1007/s13277-014-1676-8 · Cited by 44
“The mutant form of LKB1 is known to be expressed in 34 % human lung adenocarcinomas and 19 % of squamous cell carcinoma [73], and cervical and lung cancer patients possessing LKB1 mutations are known to have a poorer outcome [74, 75].”
Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and -independent pathways
Lo, B., Strasser, G. A., Sagolla, M. S., Austin, C. D., Junttila, M. R., & Mellman, I. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201208080 · Cited by 46
“…Pearson et al., 2008; Shorning et al., 2009), whereas loss of Lkb1 combined with an activated oncogene or inactivation of a second mutant tumor suppressor provokes more rapid tumor development in lung, pancreas, and various other organs (Ji et al., 2007; Huang et al., 2008; Morton et al., 2010).”
Local alignment vectors reveal cancer cell-induced ECM fiber remodeling dynamics
Lee, B., Konen, J. M., Wilkinson, S. C., Marcus, A. I., & Jiang, Y. (2017) · Scientific Reports · doi:10.1038/srep39498 · Cited by 48
Takatsu, A., Miyamoto, T., Fuseya, C., 鈴木, 昭., Kashima, H., Horiuchi, A., Ishii, K., & Shiozawa, T. (2013) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-013-1417-1 · Cited by 44
BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer
Rodríguez-Nieto, S., & Sánchez‐Céspedes, M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp035 · Cited by 49
100 years of the Warburg effect: a historical perspective
Hardie, D. G. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0173 · Cited by 48
“The latter is a rare inherited predisposition to cancer in humans, but the STK11 gene also undergoes relatively frequent somatic mutations in many sporadic cancers, especially in adenocarcinoma of the lung where it occurs in up to 20% of cases (Sanchez-Cespedes et al. 2002, Ji et al. 2007).”
BackgroundFilamin A phosphorylation by Akt promotes cell migration in response to arsenic
Li, L., Lu, Y., Stemmer, P. M., & Chen, F. (2015) · Oncotarget · doi:10.18632/oncotarget.3617 · Cited by 48
“Due to the higher frequency of mutation on the gene loci encoding LKB1, an extensively studied tumor suppressor that suppresses metastasis of the tumor cells, adenocarcinoma appears to be more metastatic compared with squamous cell carcinoma or large cell carcinoma [40, 41].”
Miao, Y., Li, A., Wang, L., Fan, C., Zhang, X., Xu, H., Yang, L., Liu, Y., & Wang, E. (2012) · Pathology & Oncology Research · doi:10.1007/s12253-012-9580-2 · Cited by 50
Self-citationNullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis
Schuster, K., Venkateswaran, N., Rabellino, A., Girard, L., Peña-Llopis, S., & Scaglioni, P. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0620-t · Cited by 43
Yeddula, N., Xia, Y., Ke, E., Beumer, J., & Verma, I. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520110112 · Cited by 43
“The LSL-Kras mouse was originally generated in the Tyler Jacks laboratory (20).”
BackgroundMethodBrock, S. E., Rendon, B. E., Yaddanapudi, K., & Mitchell, R. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.378299 · Cited by 47
“tumor-suppressive activities inmalignant cells (2, 4) andMIF is induced by the metabolic stressors, hypoxia and hypoglycemia (5, 6, 12), we set out to determine whetherMIF and D-DT functionally regulate AMPK activity in human lung adenocarcinoma cell lines.”
BackgroundInfluentialMin, R., Zun, Z., Min, Y., Wenhu, D., Wenjun, Y., & Chenping, Z. (2010) · Oral Diseases · doi:10.1111/j.1601-0825.2010.01758.x · Cited by 43
Role of AMPK and its molecular intermediates in subjugating cancer survival mechanism
Thirupathi, A., & Chang, Y. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.039 · Cited by 44
Drosten, M., Guerra, C. E., & Barbacid, M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031542 · Cited by 43
“Most of these models carry endogenous mutations in those loci known to be the key drivers in human cancer such as K-Ras, p53, Ink4a/Arf, Lkb1, Pten, etc.”
BackgroundInfluentialThe Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 57
“STK11 mutations are recorded in approximately 20–30% of NSCLC cases, with a higher prevalence in adenocarcinoma subtypes compared to squamous cell carcinomas, and they deactivate the LBK1 protein [156].”
BackgroundWang, J., Zhang, K., Wang, J., Wu, X., Liu, X., Li, B., Zhu, Y., Yu, Y., Cheng, Q., Hu, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4305 · Cited by 46
“An important role for LKB1 in cancer metastasis was demonstrated when inactivation of LKB1 significantly enhanced metastasis of lung adenocarcinomas and melanoma driven by oncogenic K-RAS [21, 22].”
InfluentialSelf-citationLiu, Y., Cheng, X., Guo, L.-X., Mao, C., Chen, Y., Liu, H., Xiao, Q., Jiang, S., Yao, Z., & Zhou, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047049 · Cited by 42
“Essential to activation of AMPK is its phosphorylation at Thr-172 by an upstream AMPK kinases (AMPKKs) [6] and tumor suppressor LKB1 [7] which is a serine/threonine kinase associated with gastrointestinal polyposis and cancer [8] and lung cancer [9].”
BackgroundEnhanced Genetic Instability and Dasatinib Sensitivity in Mammary Tumor Cells Lacking NEDD9
Singh, M. K., Izumchenko, E., Klein–Szanto, A. J., Egleston, B. L., Wolfson, M., & Golemis, E. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0353 · Cited by 42
Conditional deletion of the Lkb1 gene in the mouse mammary gland induces tumour formation
McCarthy, A., Lord, C. J., Savage, K., Grigoriadis, A. E., Smith, D. P., Weigelt, B., Reis-Filho, J. S., & Ashworth, A. (2009) · The Journal of Pathology · doi:10.1002/path.2599 · Cited by 42
“was also used to demonstrate that the Lkb1 gene can modulate lung cancer differentiation and metastasis [16].”
MethodRole of autophagy in differential sensitivity of hepatocarcinoma cells to sorafenib
Fischer, T. D. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i10.752 · Cited by 42
AMP-Activated Protein Kinase: Friend or Foe in Cancer?
Vara‐Ciruelos, D., Dandapani, M., & Hardie, D. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033619 · Cited by 43
“Confirming earlier reports ( Ji et al. 2007, Sanchez-Cespedes et al. 2002), mutations in the STK11 gene are particularly common in lung cancer, occurring in 15–20% of adenocarcinomas, 12% of non-small-cell cancers, and 10% of small-cell lung cancers.”
BackgroundResultTanaka, I., Furukawa, T., & Morise, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02165-7 · Cited by 47
Esteve‐Puig, R., Gil, R., González‐Sánchez, E., Bech‐Serra, J. J., Grueso, J., Hernández‐Losa, J., Moliné, T., Canals, F., Fábrega, B. F., Cortés, J., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004721 · Cited by 45
“This observation together with the data generated from mouse models suggests that LKB1 can behave as a haploinsufficient tumor suppressor [17,20].”
BackgroundLKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors
Wang, Y.-S., Chen, J., Cui, F., Wang, H., Wang, S., Hang, W., Zeng, Q., Quan, C., Zhai, Y.-X., Wang, J.-W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12334 · Cited by 48
“Inactivating mutations in LKB1 also lead to predisposition to sporadic cancers without PJS, such as lung adenocarcinomas, ovarian, breast, pancreatic, and cervical cancers [10–15].”
BackgroundMalhotra, J. D., Ryan, B. M., Patel, M. M., Chan, N., Guo, Y., Aisner, J., Jabbour, S. K., & Pine, S. R. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1377 · Cited by 42
“Mutated STK11 is associated with larger tumor size, more frequent lymph node or distant metastasis, and poorer overall survival (OS) (5,6).”
Swisa, A., Granot, Z., Tamarina, N. A., Sayers, S. R., Bardeesy, N. M., Philipson, L. H., Hodson, D. J., Wikström, J. D., Rutter, G. A., Leibowitz, G., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.639237 · Cited by 43
Self-citationCaiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 44
Spatial control of AMPK signaling at subcellular compartments
Chauhan, A. S., Li, Z., & Gan, B. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1727840 · Cited by 41
“While Lkb1 deletion promotes Kras-driven lung cancer growth (Ji et al. 2007), surprisingly, Ampk deletion markedly inhibited Kras-dependent lung cancer in mouse models (Eichner et al. 2019).”
BackgroundNotch Transduction in Non-Small Cell Lung Cancer
Sharif, A., Shaji, A., Chammaa, M., Pawlik, E., & Fernandez‐Valdivia, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165691 · Cited by 48
Xu, Q., Wang, C., Zhou, J., Xu, Z.-M., Gao, J., Sui, P., Walsh, C. P., Ji, H., & Xu, G. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2107599119 · Cited by 42
Self-citationSasai, K., Sukezane, T., Yanagita, E., Nakagawa, H., Hotta, A., Itoh, T., & Akagi, T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2221 · Cited by 41
Yu, S. Y. M., Chan, D. W., Liu, V. W. S., & Ngan, H. (2009) · Tumor Biology · doi:10.1159/000216843 · Cited by 42
“However, frequent mutations and deletions of LKB1 have been found in many human cancers including cervical cancer [”
BackgroundKottakis, F., & Bardeesy, N. M. (2012) · Cell Research · doi:10.1038/cr.2012.108 · Cited by 41
Self-citationZhang, L., Singh, R. R., Patel, K. P., Stingo, F. C., Routbort, M. J., You, M. J., Miranda, R. N., Garcia‐Manero, G., Kantarjian, H. M., Medeiros, L. J., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23652 · Cited by 42
“sporadic malignancies including lung cancer [43] and melanoma [44]”
BackgroundEbi, H., Tomida, S., Takeuchi, T., Arima, C., Sato, T., Mitsudomi, T., Yatabe, Y., Osada, H., & Takahashi, T. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3403 · Cited by 43
“Activation of the PI3K-AKT-mTOR axis plays a key role in growth factor receptor–mediated signaling for cancer cell growth and survival, whereas LKB1, which is inactivated in a fraction of lung adenocarcinomas (23, 24), activates AMP kinase in microenvironmental conditions, including insufficient nutrients, and leads t…”
BackgroundGao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
“5 10(7) PFU in this study), it is notable that in both murine KL mice—which displays enhanced tumor growth compared with K mice (7)—and LKB1-mutant NSCLC cell lines (35) as well as primary tumors (this study), both AMPK phosphorylation and AMPK-dependent phosphorylation of ACC are nearly completely abrogated, suggesti…”
BackgroundInfluentialThe role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLC
Wang, S., Jiang, M., Yang, Z., Huang, X., & Li, N. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.04.001 · Cited by 44
“STK11 is a major modulator of lung cancer differentiation and metastasis.(12) EGFR is an important receptor regulating RAS/MAPK, PI3K/AKT signaling pathways, and the target of EGFR-TKI (Tyrosine Kinase Inhibitor).”
BackgroundWang, Y., Luo, M., Wang, F., Tong, Y., Li, L., Shu, Y., Qiao, K., Zhang, L., Yan, G., Liu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34747-y · Cited by 42
Self-citationTsai, L.-H., Chen, P.-M., Cheng, Y.-W., Chen, C.-Y., Sheu, G.-T., Wu, T.-C., & Lee, H. (2013) · Oncogene · doi:10.1038/onc.2013.353 · Cited by 40
Modulation of Bax and mTOR for Cancer Therapeutics
Li, R., Ding, C., Zhang, J., Xie, M., Park, D., Ding, Y., Chen, G., Zhang, G., Gilbert‐Ross, M., Zhou, W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2356 · Cited by 42
“Mouse strains harboring a conditional activating mutation (G12D) at the endogenous KRAS locus and conditional LKB1 knockout were previously described (17).”
BackgroundPark, S., Han, J., & Sun, J. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.027 · Cited by 42
Tang, S., Xue, Y., Qin, Z., Fang, Z., Sun, Y., Yuan, C., Pan, Y., Zhao, Y., Tong, X., Zhang, J., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad028 · Cited by 43
“AKT1 and MYC, recently reported as oncogenic drivers in LUAS [11], are also observed enriched in Chinese LUAS.”
BackgroundResultInfluentialSelf-citationLkb1 is required for TGFβ-mediated myofibroblast differentiation
Vaahtomeri, K., Ventelä, E., Laajanen, K., Katajisto, P., Wipff, P., Hinz, B., Vallenius, T., Tiainen, M., & Mäkelä, T. P. (2008) · Journal of Cell Science · doi:10.1242/jcs.032706 · Cited by 49
“, 2007), and deletion of Lkb1 has been suggested to influence lineage choice of a common lung-cancer progenitor cell (Ji et al., 2007).”
BackgroundTargeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 38
LKB1 Suppresses p21-activated Kinase-1 (PAK1) by Phosphorylation of Thr109 in the p21-binding Domain
Deguchi, A., Miyoshi, H., Kojima, Y., Okawa, K., Aoki, M., & Taketo, M. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.079137 · Cited by 39
Lützner, N., Arce, J. D.-C., & Rösl, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032590 · Cited by 39
“suppressor p53 [11].”
Gabbasov, R. T., Xiao, F., Howe, C. G., Bickel, L. E., O’Brien, S. W., Benrubi, I. D., Do, T.-V., Zhou, Y., Nicolas, É., Cai, K. Q., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0296-y · Cited by 41
Jiang, B., Mu, Q., Qiu, F., Li, X., Xu, W., Yu, J., Fu, W., Cao, Y. B., & Wang, J. (2021) · Nature Communications · doi:10.1038/s41467-021-27017-w · Cited by 43
“The previous study has demonstrated that STK11 is a tumor suppressor and its loss-of-function mutation is involved in the morphological change from adenocarcinoma to squamous cell carcinoma, which further promotes lung cancer metastasis 49 .”
BackgroundThe role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures
Balážová, K., Clevers, H. C., & Dost, A. F. M. (2023) · eLife · doi:10.7554/elife.82998 · Cited by 46
Svensson, R. U., & Shaw, R. J. (2012) · Nature · doi:10.1038/485590a · Cited by 39
Defining the Molecular Basis of Tumor Metabolism: a Continuing Challenge Since Warburg’s Discovery
de Souza, A. C. S., Justo, G. Z., de Araújo, D. R., & Cavagis, A. D. M. (2011) · Cellular Physiology and Biochemistry · doi:10.1159/000335792 · Cited by 43
Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis
Gandhi, L., McNamara, K. L., Li, D., Borgman, C. L., McDermott, U., Brandstetter, K. A., Padera, R. F., Chirieac, L. R., Settleman, J. E., & Wong, K.-K. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0213 · Cited by 39
“These mice develop tumors generally within 4 weeks of activation of conditional mutations and die within 8 to 10 weeks, with local and distant metastases (18).”
BackgroundMethodSelf-citationPIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
“Indeed, KRAS-mediated lung carcinogenesis is reported to require elevated expression of KRAS (9) and/or alterations in the expression/activity of key tumor suppressors such as APC, ARF, INK4A, LKB1, TP53 or PTEN (10-15).”
BackgroundInfluentialCombining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
van de Haar, J., Mankor, J. M., Hummelink, K., Monkhorst, K., Smit, E. F., Wessels, L. F. A., Cuppen, E. P. J. G., Aerts, J. G. J. V., & Voest, E. E. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4027 · Cited by 51
Expression and clinical significance of NEDD9 in lung tissues
Chang, J., Gao, F., Zhao, G., & Zhang, G. (2012) · Medical Oncology · doi:10.1007/s12032-012-0213-0 · Cited by 38
“In human lung adenocarcinoma, NEDD9 expression is upregulated upon loss of the tumor suppressor serine/threonine kinase 11 (STK11, also called LKB1), and its expression is downregulated upon reexpression of LKB1 [16].”
BackgroundCardiac glycosides display selective efficacy for STK11 mutant lung cancer
Kim, N., Yim, H. Y., He, N., Lee, C., Kim, J.-H., Choi, J., Lee, H. S., Kim, S., Jeong, E., Song, M., et al. (2016) · Scientific Reports · doi:10.1038/srep29721 · Cited by 40
Dysregulation of mTOR activity through LKB1 inactivation
Zhou, W., Marcus, A. I., & Vertino, P. M. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.013.10086 · Cited by 35
“Currently, the most relevant mouse lung cancer model is the inactivation of Lkb1 in a mutant Kras background, which leads to the formation of adeno-, squamous, and large-cell carcinomas of the lung and promotes tumor metastasis [54] .”
BackgroundInfluentialMolecular Dissection of AKT Activation in Lung Cancer Cell Lines
Guo, Y., Du, J., & Kwiatkowski, D. J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0558 · Cited by 41
“Mutation of tumor suppressors including TP53, CDKN2A, PTEN, NF1, and LKB1 are also common in lung adenocarcinoma (3, 6).”
Self-citationNSP-Cas protein structures reveal a promiscuous interaction module in cell signaling
Mace, P. D., Wallez, Y., Dobaczewska, M. K., Lee, J. J., Robinson, H., Pasquale, E. B., & Riedl, S. J. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2152 · Cited by 37
Xie, M., Wu, X.-J., Zhang, J.-J., & He, C.-S. (2015) · Oncotarget · doi:10.18632/oncotarget.5361 · Cited by 38
“Our work is consistent with a recent study which indicated IL13Rα2 could be a biomarker for lung cancer especially lung adenocarcinoma [23, 24].”
ResultMetformin with Everolimus and Octreotide in Pancreatic Neuroendocrine Tumor Patients with Diabetes
Pusceddu, S., Buzzoni, R., Vernieri, C., Concas, L., Marceglia, S. R. F., Giacomelli, L., Milione, M., Leuzzi, L., Femia, D., Formisano, B., et al. (2016) · Future Oncology · doi:10.2217/fon-2015-0077 · Cited by 39
Song, N., Zhu, F., Wang, Z., Willette‐Brown, J., Xi, S., Sun, Z., Su, L., Wu, X., Ma, B., Nussinov, R., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717520115 · Cited by 44
“Notably, activating KRAS mutations are detected in ∼35% and 5% of human lung ADCs and SCCs, respectively (1, 2), suggesting that activated Kras may predominantly induce ADCs in the lung, and that inflammatory conditions may also determine the formation of lung cancer, either ADC or SCC (4).”
BackgroundInfluentialIntegration of Autophagy and Anoikis Resistance in Solid Tumors
Yang, J., Zheng, Z., Yan, X., Li, X., Liu, Z., & Ma, Z. (2013) · The Anatomical Record · doi:10.1002/ar.22769 · Cited by 39
“The first identified tumor suppressor Rb has been reported to induce autophagy and ensure the stability of the genome and reduces tumorigenesis (Jiang et al., 2010).”
BackgroundTargeting AMPK in the treatment of malignancies
Vakana, E., Altman, J. K., & Platanias, L. C. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23369 · Cited by 39
Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation
Rozenberg, G. I., Monahan, K. B., Torrice, C., Bear, J. E., & Sharpless, N. E. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e328336ee17 · Cited by 37
“Moreover, we recently described the regulation of NEDD9 and metastasis by LKB1/STK11 in a mouse model of lung cancer and the deletion of LKB1 in human samples [26].”
BackgroundMethodSelf-citationGarron, M.-L., Arsenieva, D., Zhong, J., Bloom, A. B., Lerner, A., O’Neill, G. M., & Arold, S. T. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.12.010 · Cited by 38
Hu, L. T., Wang, J., Wang, Y., Wu, C., Wu, C., Mao, B., Prasad, E. M., Wang, Y., & Chin, Y. E. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00639-1 · Cited by 37
Fang, Z., Han, X., Chen, Y., Tong, X., Xue, Y., Yao, S., Tang, S., Pan, Y., Sun, Y., Wang, X., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01227-0 · Cited by 41
Self-citationAMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
Jhaveri, T. Z., Woo, J., Shang, X., Park, B. H., & Gabrielson, E. W. (2015) · Oncotarget · doi:10.18632/oncotarget.4474 · Cited by 41
“Generally, AMPK activity appears to suppress the development and growth of cancers, overcoming growth factor signaling from oncogene activation as well as exogenous growth factors [14-16].”
Fang, B. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv090 · Cited by 41
Shi, G., & Hu, Y. (2023) · Cancers · doi:10.3390/cancers15174299 · Cited by 38
“Approximately 35–40% of human lung ADCs contain activated mutations at KRAS residue 12, 13, or 61 [4] (human lung ADC cohorts, cBioPortal for Cancer Genomics).”
BackgroundInfluentialPathological transition as the arising mechanism for drug resistance in lung cancer
Chen, Y., Tang, W. Y., Tong, X., & Ji, H. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0402-8 · Cited by 40
“EZH2, the methyltransferase responsible for catalyzing H3K27me3 [53], is highly expressed in transited SCC. Similar findings are observed in human lung SCC and the squamous component of human Ad-SCC [45].”
BackgroundInfluentialSelf-citationGerminal center kinases in immune regulation
Yin, H., Shi, Z., Jiao, S., Chen, C., Wang, W., Greene, M. I., & Zhou, Z. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.30 · Cited by 36
USP13 drives lung squamous cell carcinoma by switching lung club cell lineage plasticity
Kwon, J., Zhang, J., Mok, B., Allsup, S., Kim, C., Toretsky, J. A., & Han, C. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01892-x · Cited by 40
“Liver kinase B1 (Lkb1) has been proposed as a molecular driver of LUAD to LUSC transdifferentiation using a mouse model [86, 87].”
BackgroundGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR
Whitsett, T. G., Richer, A. L., Friel, J. M., Carson, V. M., & Inge, L. J. (2015) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s52845 · Cited by 42
Hwang, J. Y., Lee, N. S., Lee, C., Lam, K. H., Kim, H. H., Woo, J., Lin, M., Kisler, K., Choi, H., Zhou, Q., et al. (2013) · Biotechnology and Bioengineering · doi:10.1002/bit.24923 · Cited by 35
“…Wiley Periodicals, Inc. Biotechnology and Bioengineering, Vol. 110, No. 10, October, 2013 2697 Currently, the only quantitative method to assess tumor cell invasion potential is an assay of cell penetration through a Matrigel barrier (Duxbury et al., 2004; Ji et al., 2007; Kong et al., 2007).”
MethodTargeting AMPK signaling in combating ovarian cancers: opportunities and challenges
Yung, M. M. H., Ngan, H., & Chan, D. W. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv128 · Cited by 36
“In some respects, loss of LKB1 may be involved because it has been estimated to appear in up to 20% of cervical carcinomas [139] and 30% of non-small cell lung carcinomas [70,140,141].”
BackgroundKim, E. Y., Jung, J. Y., Kim, A., Chang, Y. S., & Kim, S. I. (2017) · Neoplasia · doi:10.1016/j.neo.2017.02.008 · Cited by 39
Discovery of driver non-coding splice-site-creating mutations in cancer
Cao, S., Zhou, D. C., Oh, C., Jayasinghe, R. G., Zhao, Y., Yoon, C. J., Wyczalkowski, M. A., Bailey, M. H., Tsou, T. C., Gao, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19307-6 · Cited by 41
Zebrafish Cancer Predisposition Models
Kobar, K., Collett, K., Prykhozhij, S. V., & Berman, J. N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.660069 · Cited by 40
Amelio, A. L., Fallahi, M., Schaub, F. X., Zhang, M., Lawani, M. B., Alperstein, A. S., Southern, M. R., Young, B. M., Wu, L., Zajac‐Kaye, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319176111 · Cited by 37
“Moreover, mining previously published microarray datasets generated from LKB1-null human H2126 lung carcinoma cells where LKB1 expression was restored (50) blocks CREB target gene activation (a CREB “Off” scenario) (SI Appendix, Fig.”
BackgroundMethodMalignant pleural effusion cells show aberrant glucose metabolism gene expression
Lin, C., Chen, L.-C., Tseng, V. S. M., Yan, J., Lai, W., Su, W., Lin, C., Huang, C. F., & Su, W. (2010) · European Respiratory Journal · doi:10.1183/09031936.00015710 · Cited by 37
Self-citationThe molecular mechanisms that underlie the tumor suppressor function of LKB1
Fan, D., Ma, C., & Zhang, H. (2009) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmn011 · Cited by 39
“LKB1 are particularly common in human lung cancers [ 6 ].”
BackgroundBorczuk, A., Solé, M., Lü, P., Chen, J., Wilgus, M., Friedman, R. A., Albelda, S. Μ., & Powell, C. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1590 · Cited by 36
“To determine the relative similarity of the KrasTgfbr2 / model with other murine lung adenocarcinoma models, we tested gene signatures from (i) the KrasTgfbr2 / model (this article); (ii) the noninvasiveKras-LAmodel (14, 20); (iii) the KrasP53mut model (21); (iv) the KrasLkb1 / , model (22); and (v) the KrasHif2amodel…”
MethodLiu, Y., Li, Y., Wang, X., Liu, F., Gao, P., Quinn, M. M., Li, F., Merlino, A. A., Benes, C., Liu, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0567 · Cited by 33
“Inactivation of LKB1 not only alters cellular metabolic processes (1,13-15), but also induces a more aggressive tumor phenotype (16-19).”
Self-citationLineage plasticity and histological transformation: tumor histology as a spectrum
Li, X., Gardner, E. E., Molina‐Pinelo, S., Wilhelm, C., Mu, P., & Quintanal-Villalonga, À. (2025) · Cell Research · doi:10.1038/s41422-025-01180-x · Cited by 38
“Using a series of lineage tracing GEMMs, including Cgrp CreER ;Trp53 f/f ;Rb1 f/f ;Pten f/f (TKO (triple knockout), Cgrp CreER ;TKO; Rosa26 mTmG , and inducible YAP overexpression models ( Cgrp CreER ;TKO;TetOn-YAPS127A and Cgrp CreER ;TKO;TetOn-YAP5SA ), in combination with Rbpj f/f to modulate Notch signaling, these…”
InfluentialNSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy
Xu, C., Buczkowski, K. A., Zhang, Y., Asahina, H., Beauchamp, E. M., Terai, H., Li, Y. Y., Meyerson, M. M., Wong, K., & Hammerman, P. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0077 · Cited by 34
“Thismixed phenotype is not unique to the tumors induced by DDR2L63V and has been previously reported with inducible deletion of the tumor-suppressor Lkb1 along with Kras mutant (5).”
Self-citationEsmatabadi, M. J. D., Farhangi, B., Safari, Z., Kazerooni, H., Shirzad, H., Zolghadr, F., & Sadeghizadeh, M. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.6.2473 · Cited by 33
Dakir, E. H., Feigenbaum, L., & Linnoila, R. I. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn190 · Cited by 34
“In another study, a somatically activatable mutant Kras-driven model of mouse lung cancer was used to evaluate the role of LKB1 and other tumor suppressors in lung carcinogenesis ( 46 ).”
BackgroundOh, A.-Y., Jung, Y. S., Kim, J., Lee, J., Cho, J.-H., Chun, H.-Y., Park, S., Park, H., Lim, S. E. S., Ha, N., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1025 · Cited by 34
Lee, H. M., Muhammad, N., Lieu, E. L., Cai, F., Mu, J., Ha, Y., Cao, G., Suchors, C., Joves, K., Chronis, C., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01066-z · Cited by 37
Lewandowska, M. A., Czubak, K., Klonowska, K., Jóźwicki, W., Kowalewski, J., & Kozłowski, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117983 · Cited by 32
Beyond Standard Adjuvant Therapy for Colon Cancer: Role of Nonstandard Interventions
Meyerhardt, J. A. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.007 · Cited by 32
Metadata
- Authors
- Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., Liang, M.-C., Cai, D., Naumov, G. N., Bao, L., Contreras, C. M., Li, D., Chen, L., Krishnamurthy, J., Koivunen, J., Chirieac, L. R., Padera, R. F., Bronson, R. T., Lindeman, N. I., Christiani, D. C., Lin, X., Shapiro, G. I., Jänne, P. A., Johnson, B. E., Meyerson, M., Kwiatkowski, D. J., Castrillon, D. H., Bardeesy, N., Sharpless, N. E., & Wong, K.-K.
- Affiliations
- Dana-Farber Cancer Institute (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- University of Tennessee Health Science Center (US)
- Harold C. Simmons Comprehensive Cancer Center (US)
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- ORCID
- Ji, Hongbin
- Ramsey, Matthew R.
- Hayes, D. Neil
- Wu, Michael C.
- Shimamura, Takeshi
- Perera, Samanthi A.
- Liang, Mei-Chih
- Bao, Lei
- Chen, Liang
- Koivunen, Jussi
- Chirieac, Lucian R.
- Padera, Robert F.
- Bronson, Roderick T.
- Lindeman, Neal I.
- Christiani, David C.
- Lin, Xihong
- Shapiro, Geoffrey I.
- Johnson, Bruce E.
- Meyerson, Matthew
- Kwiatkowski, David J.
- Bardeesy, Nabeel
- Sharpless, Norman E.
- Wong, Kwok-Kin
- Venue
- Nature
- Published
- 2007-08-05
- Volume
- 448
- Issue
- 7155
- Pages
- 807-810
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2134964552
- Cited by
- 1,064
- References
- 36
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 44 · 2023: 66 · 2022: 50 · 2021: 71 · 2020: 51 · 2019: 66 · 2018: 61 · 2017: 56 · 2016: 54 · 2015: 72 · 2014: 83 · 2013: 65 · 2012: 52
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- LKB1, STK11, lung cancer, tumour suppressor, metastasis, squamous cell carcinoma, non-small cell lung cancer, KRAS, p53, Ink4a/Arf, CDKN2A, tumor differentiation, Peutz-Jeghers syndrome, metastasis-promoting genes
- MeSH terms
- AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Cell Differentiation, Disease Models, Animal, Humans, Lung Neoplasms, Neoplasm Metastasis, Genes, ras, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Genes, p53, Protein Serine-Threonine Kinases, Genes, p16, Gene Expression Profiling, Cell Line, Tumor, Mice, Genes, Neoplasm, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.